Lyell Immunopharma LYEL
NASDAQ LYEL
$9.46 +0.05 (+0.53%)
As of: Oct 2, 2026 · 11:40 AM EDT

Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2026)

Updated

Lyell Immunopharma's Cash from Financing Activities came in at $522,000 for Q2 2026, up 185.2% from $183,000 a year earlier but down 99.0% from the prior quarter.

Analysis

Lyell Immunopharma (LYEL) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Lyell Immunopharma reported Cash from Financing Activities of $102.47 million; for FY2025, it came in at $50.41 million.

  • Cash from Financing Activities carries a five-year compound annual growth rate of -36.2% (FY2020 to FY2025).
  • Going back by year, Cash from Financing Activities was $1.33 million in FY2024 (-23.9%), $1.74 million in FY2023 (-83.6%), $10.64 million in FY2022 (-97.3%) and $401.24 million in FY2021 (-15.8%).
  • The five-year range for quarterly Cash from Financing Activities is -$531,000 (Q3 2021) to $51.72 million (Q1 2026).
  • Year-over-year, Cash from Financing Activities increased in 1 of the last five quarters, with an average decline of 16.3%.
  • The fastest year-over-year change in Cash from Financing Activities over five years came in Q1 2022 (growth of 189.0%), and the weakest in Q2 2022 (a decline of 99.4%).
  • Business Quant data shows LYEL's Cash from Financing Activities at $51.72 million (Q1 2026), $222,000 (Q4 2025) and $50 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Lyell Immunopharma 229.06 Mn 229.06 Mn - 522,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 522,000.00
Mar 31, 2026 51.72 Mn
Dec 31, 2025 222,000.00
Sep 30, 2025 50.00 Mn
Jun 30, 2025 183,000.00
Mar 31, 2025 1,000.00
Dec 31, 2024 437,000.00
Jun 30, 2024 862,000.00
Mar 31, 2024 27,000.00
Dec 31, 2023 759,000.00
Sep 30, 2023 -143,000.00
Jun 30, 2023 1.20 Mn
Mar 31, 2023 -69,000.00
Dec 31, 2022 863,000.00
Sep 30, 2022 4.76 Mn
Jun 30, 2022 2.46 Mn
Mar 31, 2022 2.56 Mn
Dec 31, 2021 7.40 Mn
Sep 30, 2021 -531,000.00
Jun 30, 2021 393.49 Mn
API Access

Lyell Immunopharma Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=LYEL&period=max&api_key=YOUR_API_KEY